[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100217434":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":42,"centralContacts":34,"locations":46,"responsibleParty":202,"collaborators":204,"id":206,"slug":207,"hasResults":208,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":34,"eligibilityCriteria":212,"healthyVolunteers":213,"sex":214,"minAge":215,"maxAge":34,"enrollmentInfo":216,"targetDuration":34,"studyType":219,"phases":220,"briefSummary":222,"conditions":223,"keywords":229,"overallStatus":242,"whyStopped":34,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":252},{"fullName":5,"class":6},"Seqirus","INDUSTRY",[8,14,18,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: aH5N1 adult","EXPERIMENTAL","aH5N1 healthy and non-healthy adults",[13],"Biological: Novartis Investigational H5N1 vaccine",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2: aH5N1 elderly","aH5N1 healthy and non-healthy elderly",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Arm 4: aTIV elderly","ACTIVE_COMPARATOR","aTIV healthy and non-healthy elderly",[23],"Biological: Novartis Seasonal Influenza Vaccine",{"label":25,"type":20,"description":26,"interventionNames":27},"Arm 3: aTIV adult","aTIV healthy and non-healthy adults",[23],[29,35,37,40],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"BIOLOGICAL","Novartis Investigational H5N1 vaccine","2 doses of 0.5 ml, 3 weeks apart",[9],null,{"type":30,"name":31,"description":32,"armGroupLabels":36,"otherNames":34},[15],{"type":30,"name":38,"description":32,"armGroupLabels":39,"otherNames":34},"Novartis Seasonal Influenza Vaccine",[19],{"type":30,"name":38,"description":32,"armGroupLabels":41,"otherNames":34},[25],[43],{"name":44,"affiliation":44,"role":45},"Novartis Vaccines","STUDY_CHAIR",[47,60,65,74,86,96,106,115,126,131,140,149,159,169,178,188,196],{"facility":48,"status":34,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":34},"102, Novartis Investigational Site","Darlinghurst","New South Wales","2010","Australia","AU",{"type":55,"coordinates":56},"Point",[57,58],151.21925,-33.87939,{"lat":58,"lon":57},{"facility":61,"status":34,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":62,"geoPoint":64,"contacts":34},"103, Novartis Investigational Site",{"type":55,"coordinates":63},[57,58],{"lat":58,"lon":57},{"facility":66,"status":34,"city":67,"state":50,"zip":68,"country":52,"countryCode":53,"cosmosGeoPoint":69,"geoPoint":73,"contacts":34},"101, Novartis Investigational Site","Merewether","2291",{"type":55,"coordinates":70},[71,72],151.74325,-32.94801,{"lat":72,"lon":71},{"facility":75,"status":34,"city":76,"state":77,"zip":78,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":85,"contacts":34},"303, Novartis Investiagtional Site","Würzburg","Bavaria","97070","Germany","DE",{"type":55,"coordinates":82},[83,84],9.95121,49.79391,{"lat":84,"lon":83},{"facility":87,"status":34,"city":88,"state":89,"zip":90,"country":79,"countryCode":80,"cosmosGeoPoint":91,"geoPoint":95,"contacts":34},"302, Novartis Investigational Site","Hamburg","Free and Hanseatic City of Hamburg","39120",{"type":55,"coordinates":92},[93,94],9.99302,53.55073,{"lat":94,"lon":93},{"facility":97,"status":34,"city":98,"state":99,"zip":100,"country":79,"countryCode":80,"cosmosGeoPoint":101,"geoPoint":105,"contacts":34},"304, Novartis Investigational Site","Rostock","Mecklenburg-Vorpommern","18057",{"type":55,"coordinates":102},[103,104],12.14049,54.0887,{"lat":104,"lon":103},{"facility":107,"status":34,"city":108,"state":109,"zip":90,"country":79,"countryCode":80,"cosmosGeoPoint":110,"geoPoint":114,"contacts":34},"301, Novartis Investigational Site","Magdeburg","Saxony-Anhalt",{"type":55,"coordinates":111},[112,113],11.63189,52.13129,{"lat":113,"lon":112},{"facility":116,"status":34,"city":117,"state":117,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":121,"geoPoint":125,"contacts":34},"005, Novartis Investigational Site","Chieti","66013","Italy","IT",{"type":55,"coordinates":122},[123,124],14.16494,42.34827,{"lat":124,"lon":123},{"facility":127,"status":34,"city":117,"state":117,"zip":118,"country":119,"countryCode":120,"cosmosGeoPoint":128,"geoPoint":130,"contacts":34},"008, Novartis Investigational Site",{"type":55,"coordinates":129},[123,124],{"lat":124,"lon":123},{"facility":132,"status":34,"city":133,"state":117,"zip":134,"country":119,"countryCode":120,"cosmosGeoPoint":135,"geoPoint":139,"contacts":34},"082, Novartis Investigational Site","Fossacesia","66022",{"type":55,"coordinates":136},[137,138],14.48339,42.24198,{"lat":138,"lon":137},{"facility":141,"status":34,"city":142,"state":117,"zip":143,"country":119,"countryCode":120,"cosmosGeoPoint":144,"geoPoint":148,"contacts":34},"081, Novartis Investigational Site","Lanciano","66034",{"type":55,"coordinates":145},[146,147],14.39024,42.22718,{"lat":147,"lon":146},{"facility":150,"status":34,"city":151,"state":152,"zip":153,"country":119,"countryCode":120,"cosmosGeoPoint":154,"geoPoint":158,"contacts":34},"003, Novartis Investigational Site","Monza","Milan","20052",{"type":55,"coordinates":155},[156,157],9.27246,45.58005,{"lat":157,"lon":156},{"facility":160,"status":34,"city":161,"state":162,"zip":163,"country":119,"countryCode":120,"cosmosGeoPoint":164,"geoPoint":168,"contacts":34},"007, Novartis Investigational Site","Aviano","Padova","33080",{"type":55,"coordinates":165},[166,167],12.59472,46.07056,{"lat":167,"lon":166},{"facility":170,"status":34,"city":171,"state":171,"zip":172,"country":119,"countryCode":120,"cosmosGeoPoint":173,"geoPoint":177,"contacts":34},"004, Novartis Investigational Site","Parma","43100",{"type":55,"coordinates":174},[175,176],10.32618,44.79935,{"lat":176,"lon":175},{"facility":179,"status":34,"city":180,"state":181,"zip":182,"country":119,"countryCode":120,"cosmosGeoPoint":183,"geoPoint":187,"contacts":34},"006, Novartis Investigational Site","San Daniele del Friuli","Udine","33038",{"type":55,"coordinates":184},[185,186],13.00726,46.15714,{"lat":186,"lon":185},{"facility":189,"status":34,"city":152,"state":34,"zip":190,"country":119,"countryCode":120,"cosmosGeoPoint":191,"geoPoint":195,"contacts":34},"001, Novartis Investigational Site","20127",{"type":55,"coordinates":192},[193,194],9.18951,45.46427,{"lat":194,"lon":193},{"facility":197,"status":34,"city":152,"state":34,"zip":198,"country":119,"countryCode":120,"cosmosGeoPoint":199,"geoPoint":201,"contacts":34},"002, Novartis Investigational Site","20157",{"type":55,"coordinates":200},[193,194],{"lat":194,"lon":193},{"type":203,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR",[205],{"name":44,"class":6},"100217434","phase-3-safety-and-immunogenicity-of-two-doses-of-ah5n1-vaccine-in-adult-and-elderly-subjects-with-and-without-immunosuppressive-conditions-ah5n1monovalent-h5n1-influenza-vaccine-100217434",false,"NCT02107807","Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine","A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions","Inclusion Criteria:\n\n* Male and female individuals 18 years of age and older at the time of enrollment who are mentally competent, willing and able to understand the nature and risks of the proposed study, and able to sign the consent form prior to study entry;\n* Individuals who are able to comply with all study procedures and requirements;\n* Healthy volunteers and volunteers specifically HIV positive, transplant recipients, cancer patients may be eligible;\n* Please contact the site for additional eligibility criteria.\n\nExclusion Criteria:\n\n* Individuals who are not able to follow all the required study procedures for the whole period of the study;\n* Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study;\n* Please contact the site for additional eligibility criteria.",true,"ALL","18 Years",{"count":217,"type":218},539,"ACTUAL","INTERVENTIONAL",[221],"PHASE3","Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without immunosuppressive conditions.",[224,225,226,227,228],"Influenza, Human","Flu, Human","Flu, Avian","Influenza","Influenza A Virus, H5N1 Subtype",[230,231,232,233,234,235,236,237,238,239,240,241],"Influenza,","H5N1","aH5N1","H5N1 vaccine","Pandemic Influenza vaccine","MF59","Adjuvant","Avian flu","Underlying Immunosuppressive","immunosuppressive conditions","Pandemic vaccine","Adjuvanted vaccine","COMPLETED","2016-05-05",{"date":245,"type":246},"2016-05-09","ESTIMATED",{"date":248,"type":34},"2014-04",{"date":250,"type":218},"2015-05",{"name":5,"class":6},17]